High CXCL6 drives matrix expression and correlate with markers of poor outcome in IPF
Bahudhanapati, H.; Tan, J.; Apel, R.-M.; Seeliger, B.; Li, X.; Chen, T.-Y.; Sullivan, D.; Sembrat, J.; Rojas, M.; Valenzi, E.; Lafyatis, R. A.; Jawale, C.; Biswas, P.; Tedrow, J.; Adams, T. S.; Kaminski, N.; Wuyts, W. A.; McDyer, J. F.; Alder, J. K.; Zhang, Y.; Nouraie, M.; Prasse, A.; Kass, D. J.
Show abstract
Signaling via G protein-coupled receptors (GPCRs) can modulate levels of cyclic adenosine monophosphate (cAMP) and shape the functions of fibroblasts in idiopathic pulmonary fibrosis (IPF). We have identified Chemokine (C-X-C) Motif Ligand 6 (CXCL6) as a potential pro-fibrotic GPCR ligand. We tested the function of CXCL6 in ex vivo human donor and fibrotic lung fibroblasts and in an animal model of pulmonary fibrosis. We also measured levels of CXCL6 in the blood and bronchoalveolar lavage (BAL) of patients with IPF. CXCL6 decreased cAMP levels in a dose-dependent manner in Donor and IPF Fibroblasts. CXCL6 mRNA and protein were localized to epithelial cells. Administration of mCXCL5 (LIX, murine CXCL6 homologue) to mice increased collagen synthesis with and without bleomycin. CXCL6 increased Collagen I and -SMA levels in Donor and IPF Fibroblasts. Silencing of CXCR1/2 as well as Reparixin, a CXCR1/2 inhibitor, blocked effects of CXCL6. Treprostinil blocked effects of CXCL6 only on levels of -SMA but not on Collagen I. CXCL6 levels in the BAL of two separate cohorts of patients with IPF was associated with poor survival. We conclude that high CXCL6 drives fibroblast function and correlates with poor outcomes in IPF.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.